HUE029912T2 - Treatments using an ammonia binding agent - Google Patents
Treatments using an ammonia binding agent Download PDFInfo
- Publication number
- HUE029912T2 HUE029912T2 HUE09739263A HUE09739263A HUE029912T2 HU E029912 T2 HUE029912 T2 HU E029912T2 HU E09739263 A HUE09739263 A HU E09739263A HU E09739263 A HUE09739263 A HU E09739263A HU E029912 T2 HUE029912 T2 HU E029912T2
- Authority
- HU
- Hungary
- Prior art keywords
- hpn
- pba
- pagn
- patient
- ammonia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9323408P | 2008-08-29 | 2008-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE029912T2 true HUE029912T2 (en) | 2017-03-28 |
Family
ID=45604478
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09739263A HUE029912T2 (en) | 2008-08-29 | 2009-01-07 | Treatments using an ammonia binding agent |
HUE16176456A HUE040503T2 (hu) | 2008-08-29 | 2009-01-07 | Kezelési eljárások ammónia-leválasztó gyógyszerek használatával |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16176456A HUE040503T2 (hu) | 2008-08-29 | 2009-01-07 | Kezelési eljárások ammónia-leválasztó gyógyszerek használatával |
Country Status (10)
Country | Link |
---|---|
JP (3) | JP5577341B2 (lt) |
DK (1) | DK3133396T3 (lt) |
ES (2) | ES2593378T3 (lt) |
HR (2) | HRP20161222T1 (lt) |
HU (2) | HUE029912T2 (lt) |
LT (2) | LT3133396T (lt) |
PL (1) | PL2330892T3 (lt) |
PT (2) | PT3133396T (lt) |
SI (1) | SI3133396T1 (lt) |
TR (1) | TR201816616T4 (lt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140094517A (ko) | 2011-09-30 | 2014-07-30 | 하이페리온 쎄라퓨틱스, 인크. | 질소 스캐빈징 약물들의 치료학적 모니터링 방법들 |
CN104540507A (zh) * | 2012-04-20 | 2015-04-22 | 海波龙治疗公司 | 苯乙酸前药的治疗性监测方法 |
JP2016506378A (ja) * | 2012-11-21 | 2016-03-03 | ハイペリオン セラピューティクス,インコーポレイテッド | 肝性脳症の治療のための窒素除去薬の投与方法および評価方法 |
US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
US20220044801A1 (en) * | 2018-10-04 | 2022-02-10 | Atonarp Inc. | Living body information acquisition system, health management server, and system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4284647A (en) * | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
ES2157422T3 (es) * | 1995-02-07 | 2001-08-16 | Brusilow Entpr Llc | Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos. |
US20070004805A1 (en) * | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
-
2009
- 2009-01-07 DK DK16176456.8T patent/DK3133396T3/en active
- 2009-01-07 ES ES09739263.3T patent/ES2593378T3/es active Active
- 2009-01-07 JP JP2011525021A patent/JP5577341B2/ja active Active
- 2009-01-07 HU HUE09739263A patent/HUE029912T2/en unknown
- 2009-01-07 PT PT16176456T patent/PT3133396T/pt unknown
- 2009-01-07 ES ES16176456T patent/ES2695534T3/es active Active
- 2009-01-07 LT LTEP16176456.8T patent/LT3133396T/lt unknown
- 2009-01-07 TR TR2018/16616T patent/TR201816616T4/tr unknown
- 2009-01-07 SI SI200931886T patent/SI3133396T1/sl unknown
- 2009-01-07 PT PT97392633T patent/PT2330892T/pt unknown
- 2009-01-07 PL PL09739263T patent/PL2330892T3/pl unknown
- 2009-01-07 LT LTEP09739263.3T patent/LT2330892T/lt unknown
- 2009-01-07 HU HUE16176456A patent/HUE040503T2/hu unknown
- 2009-08-27 JP JP2011525214A patent/JP2012501451A/ja not_active Withdrawn
-
2014
- 2014-01-07 JP JP2014000920A patent/JP2014102255A/ja not_active Withdrawn
-
2016
- 2016-09-26 HR HRP20161222TT patent/HRP20161222T1/hr unknown
-
2018
- 2018-11-08 HR HRP20181877TT patent/HRP20181877T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PT2330892T (pt) | 2016-09-05 |
PL2330892T3 (pl) | 2017-05-31 |
LT2330892T (lt) | 2016-11-25 |
SI3133396T1 (sl) | 2018-12-31 |
DK3133396T3 (en) | 2018-12-03 |
HUE040503T2 (hu) | 2019-03-28 |
JP2012501329A (ja) | 2012-01-19 |
ES2695534T3 (es) | 2019-01-08 |
JP5577341B2 (ja) | 2014-08-20 |
HRP20161222T1 (hr) | 2017-02-10 |
TR201816616T4 (tr) | 2018-11-21 |
PT3133396T (pt) | 2018-12-07 |
HRP20181877T1 (hr) | 2019-01-11 |
LT3133396T (lt) | 2018-11-26 |
JP2014102255A (ja) | 2014-06-05 |
ES2593378T3 (es) | 2016-12-09 |
JP2012501451A (ja) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2330892T3 (en) | METHODS OF TREATMENT WITH USE OF AMMONIAK COLLECTIVE MEDICINES | |
US20120022157A1 (en) | Dosing and monitoring patients on nitrogen-scavenging drugs | |
US10183006B2 (en) | Methods of therapeutic monitoring of nitrogen scavenging drugs | |
Faggiano et al. | Nephrolithiasis in Cushing’s disease: prevalence, etiopathogenesis, and modification after disease cure | |
Mokhtarani et al. | Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders | |
US20180015058A1 (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
HUE029912T2 (en) | Treatments using an ammonia binding agent | |
Young Jr et al. | l‐Thyroxine contamination of pharmaceutical d‐thyroxine: probable cause of therapeutic effect | |
EP2986325B1 (en) | Methods of treating urea cycle disorders | |
Anderson et al. | A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers | |
TW202339759A (zh) | PPARẟ促效劑於治療疾病之用途 |